Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Injection Human Interleukin 2 Market Growth From $1.32 Billion In 2026 To $1.95 Billion By 2030 At A CAGR Of 10.2%
The market for injection human interleukin 2 has seen substantial expansion in recent years. It is anticipated to grow from $1.21 billion in 2025 to $1.33 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.2%. The historical growth can be linked to the early achievements of cytokine-based immunotherapy, an increase in cancer diagnoses, advancements in recombinant protein manufacturing, a rise in hospital-based oncology treatments, and regulatory authorizations for IL-2 therapies.
The injection human interleukin 2 market is projected to experience substantial growth over the coming years. It is anticipated to expand to $1.96 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.2%. This expected expansion throughout the forecast period can be attributed to several factors, including the rise in cancer immunotherapy pipelines, increased utilization of il-2 with checkpoint inhibitors, advancements in targeted immune activation, growing investment in biologic oncology drugs, and the broadening of precision immunotherapy approaches. Noteworthy trends predicted for the forecast period include the increasing application of il-2 in combination immunotherapies, a greater adoption of recombinant human interleukin 2, the expansion of il-2’s uses in oncology, an escalating focus on dose optimization to mitigate toxicity, and intensified clinical research within immune modulation.
Get A Free Sample Report With In-Depth Market Insights:
Injection Human Interleukin 2 Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
A growing emphasis on personalized medicine is expected to propel the expansion of the injection human interleukin 2 market in the future. This medical approach involves customizing treatment and prevention methods to suit an individual’s distinct genetic profile, lifestyle, and environmental factors. The heightened demand for personalized medicine stems from advancements in genetic testing, facilitating more precise diagnoses and individualized treatments that are specifically adapted to patient profiles, thereby enhancing results and mitigating adverse effects. Injection Human Interleukin 2 facilitates personalized medicine by allowing its application in customized immunotherapy protocols, wherein IL-2 is given according to a patient’s particular immune characteristics to optimize therapeutic efficacy and lessen negative reactions. As an illustration, in February 2024, a report from the Personalized Medicine Coalition, a US-based non-profit organization, indicated that the FDA approved 16 new personalized medicines for rare disease patients in 2023, an increase from only six in 2022. Consequently, the growing emphasis on personalized medicine is set to stimulate the expansion of the injection human interleukin 2 market.
Injection Human Interleukin 2 Market Segment Trends And Revenue Contributors
The injection human interleukin 2 market covered in this report is segmented –
1) By Product Type: Recombinant Human Interleukin 2, Natural Human Interleukin 2
2) By Route Of Administration: Subcutaneous Injection, Intravenous Injection, Intramuscular Injection
3) By Distribution Channel: Direct Sales, Pharmacies, Online Sales
4) By Application: Oncology, Immunotherapy, Autoimmune Diseases
5) By End-User: Hospitals, Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Recombinant Human Interleukin 2: Escherichia Coli Derived Interleukin 2, Yeast Derived Interleukin 2, Mammalian Cell Derived Interleukin 2
2) By Natural Human Interleukin 2: Plasma Derived Interleukin 2, Peripheral Blood Mononuclear Cell Derived Interleukin 2
Injection Human Interleukin 2 Market Innovation Trends Shaping Future Development
Major companies in the injection human interleukin-2 market are concentrating on developing novel solutions, such as low-dose interleukin-2, to facilitate extended treatment durations. This therapeutic approach, low-dose interleukin-2, involves administering small quantities of IL-2 to specifically activate regulatory T cells, thereby improving immune tolerance while simultaneously reducing inflammation and side effects. For instance, in October 2024, Coya Therapeutics Inc., a US-based biotechnology firm, announced the outcomes of a double-blind study concerning the effects of subcutaneous low-dose interleukin-2 (LD IL-2) in Alzheimer’s disease (AD). The investigation successfully achieved its primary and secondary goals, showing an increase in regulatory T cells (Tregs) without impacting T effector lymphocytes. Further exploratory findings indicated that low-dose IL-2 (LD IL-2) administered every four weeks contributed to cognitive stabilization, enhanced cerebrospinal fluid (CSF) soluble Aβ42 levels, and stabilized CSF Neurofilament Light Chain (NfL). These results reinforce the potential of employing Treg modulation for treating neurodegenerative conditions, particularly Alzheimer’s. COYA 301, an experimental low-dose IL-2, aims to improve Treg function through subcutaneous delivery for inflammatory control.
Injection Human Interleukin 2 Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the injection human interleukin 2 market are F. Hoffmann-La Roche AG, Novartis AG, Merck & Co. Inc., Bristol Myers Squibb, Sanofi S.A., Pfizer Inc., Amgen Inc., Nektar Therapeutics, Synthekine Inc., Xilio Therapeutics Inc., Iovance Biotherapeutics Inc., Clinigen Group plc, BeiGene Ltd., Shanghai Fosun Pharmaceutical Group Co. Ltd., Beijing SL Pharmaceutical Co. Ltd., Shandong Quangang Pharmaceutical Co. Ltd., PeproTech Inc., Qkine Ltd., Akron Biotechnology LLC, Thermo Fisher Scientific Inc.
View The Full Injection Human Interleukin 2 Market Report:
Injection Human Interleukin 2 Market Largest Region By Revenue And Market Share
North America was the largest region in the injection human interleukin 2 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the injection human interleukin 2 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model